Computer-aided detection (CAD) firm iCAD saw revenue grow 30% in the company's second quarter (end-June 30), driven by stronger sales of therapy products.
For the quarter, iCAD had total revenues of $7.7 million, compared with $5.9 million in sales for the second quarter of 2012. The growth was driven by a 161% increase in sales in the company's Therapy division, which offset a 14% decline in revenues in its Cancer Detection segment, which includes its CAD software business.
The company posted a net loss for the most recent quarter of $1.9 million, compared with a net loss for the second quarter of 2012 of $2.9 million.
iCAD said the second-quarter results represented the firm's fourth consecutive quarter of double-digit revenue growth and profitability based on adjusted earnings before interest, taxes, depreciation, and amortization (EDITDA).
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
